Advertisement

Risk of Recurrent Venous Thromboembolism After an Initial Episode: Risk Stratification and Implications for Long-term Treatment

  • Vineet Agrawal
  • Esther S. H. KimEmail author
Peripheral Vascular Disease (Christopher J. Cooper and Rajesh Gupta, Section Editors)
  • 170 Downloads
Part of the following topical collections:
  1. Topical Collection on Peripheral Vascular Disease

Abstract

Purpose of Review

Venous thromboembolism (VTE) is a common condition with significant associated morbidity and mortality. Recurrent VTE after an initial episode is a preventable medical condition. The following review discusses data supporting recurrence risk estimates after an initial VTE episode as well as treatment strategies to mitigate risk of recurrent VTE.

Recent Findings

This review particularly highlights methods for stratifying the risk of recurrent VTE and recent studies that have evaluated direct oral anticoagulants for the prevention of recurrent VTE.

Summary

Risk assessment for VTE recurrence should guide anticoagulation duration. In patients who present with unprovoked VTE events, there remains a high risk of recurrence that is significantly mitigated with extended duration anticoagulation with either a vitamin K antagonist or direct oral anticoagulant.

Keywords

Venous thromboembolic disease Deep venous thrombosis Pulmonary embolism Anticoagulation Risk assessment Recurrence 

Notes

Compliance with Ethical Standards

Conflict of Interest

Vineet Agrawal and Esther S.H. Kim declare that they have no conflicts of interest.

Human Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism. Am J Prev Med. 2010;38:S495–501.CrossRefGoogle Scholar
  2. 2.
    Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558–63.CrossRefGoogle Scholar
  3. 3.
    White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:4I–8.CrossRefGoogle Scholar
  4. 4.
    Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis. 2006;21:23–9.CrossRefGoogle Scholar
  5. 5.
    Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost. 2014;112:255–63.CrossRefGoogle Scholar
  6. 6.
    Lefebvre P, Laliberté F, Nutescu EA, Duh M, LaMori J, Bookhart BK, et al. All-cause and disease-related health care costs associated with recurrent venous thromboembolism. Thromb Haemost. 2013;110:1288–97.CrossRefGoogle Scholar
  7. 7.
    Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet (London, England). 2003;362:523–6.CrossRefGoogle Scholar
  8. 8.
    Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107:I9–16.CrossRefGoogle Scholar
  9. 9.
    White RH. Identifying risk factors for venous thromboembolism. Circulation. 2012;125:2051–3.CrossRefGoogle Scholar
  10. 10.
    •• Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing G-J, Kyrle PA, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14:1480–3 An important guideline statement from the ISTH that specifically defines provoked and unprovoked venous thromboembolism.CrossRefGoogle Scholar
  11. 11.
    Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor. Arch Intern Med. 2010;170:1710–6.PubMedGoogle Scholar
  12. 12.
    •• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease. Chest. 2016;149:315–52 The most recent set of comprehensive guidelines that provide recommendations and literature review on the diagnosis, management, and prevention of venous thromboembolism.CrossRefGoogle Scholar
  13. 13.
    Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199–205.CrossRefGoogle Scholar
  14. 14.
    Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3–14.CrossRefGoogle Scholar
  15. 15.
    de Haan HG, van Hylckama Vlieg A, van der Gaag KJ, de Knijff P, Rosendaal FR. Male-specific risk of first and recurrent venous thrombosis: a phylogenetic analysis of the Y chromosome. J Thromb Haemost. 2016;14:1971–7.CrossRefGoogle Scholar
  16. 16.
    Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153:523–31.CrossRefGoogle Scholar
  17. 17.
    Roach REJ, Lijfering WM, Rosendaal FR, Cannegieter SC, le Cessie S. Sex difference in risk of second but not of first venous thrombosis clinical perspective. Circulation. 2014;129:51–6.CrossRefGoogle Scholar
  18. 18.
    Roach REJ, Lijfering WM, Tait RC, Baglin T, Kyrle PA, Cannegieter SC, et al. Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. J Thromb Haemost. 2015;13:1815–22.CrossRefGoogle Scholar
  19. 19.
    McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet (London, England). 2006;368:371–8.CrossRefGoogle Scholar
  20. 20.
    Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC. Body height, mobility, and risk of first and recurrent venous thrombosis. J Thromb Haemost. 2015;13:548–54.CrossRefGoogle Scholar
  21. 21.
    Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168:1678–83.CrossRefGoogle Scholar
  22. 22.
    Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761–8.CrossRefGoogle Scholar
  23. 23.
    White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med. 1998;128:737–40.CrossRefGoogle Scholar
  24. 24.
    White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005;93:298–305.CrossRefGoogle Scholar
  25. 25.
    Kort D, van Rein N, van der Meer FJM, Vermaas HW, Wiersma N, Cannegieter SC, et al. Relationship between neighborhood socioeconomic status and venous thromboembolism: results from a population-based study. J Thromb Haemost. 2017;15:2352–60.CrossRefGoogle Scholar
  26. 26.
    Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation. JAMA. 2009;301:2472.CrossRefGoogle Scholar
  27. 27.
    Sokol J, Timp JF, le Cessie S, van Hylckama-Vlieg A, Rosendaal FR, Kubisz P, et al. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study. J Thromb Haemost. 2018;16:680–8.CrossRefGoogle Scholar
  28. 28.
    Ospina-Romero M, Cannegieter SC, den Heijer M, Doggen CJM, Rosendaal FR, Lijfering WM. Hyperhomocysteinemia and risk of first venous thrombosis: the influence of (unmeasured) confounding factors. Am J Epidemiol. 2018;187:1392–400.  https://doi.org/10.1093/aje/kwy004.CrossRefPubMedGoogle Scholar
  29. 29.
    Lijfering WM, Mulder R, ten Kate MK, Veeger NJGM, Mulder AB, van der Meer J. Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives. Blood. 2009;113:1225–30.CrossRefGoogle Scholar
  30. 30.
    Lijfering WM, Christiansen SC, Rosendaal FR, Cannegieter SC. Contribution of high factor VIII, IX and XI to the risk of recurrent venous thrombosis in factor V Leiden carriers. J Thromb Haemost. 2009;7:1944–6.CrossRefGoogle Scholar
  31. 31.
    Lijfering WM, Middeldorp S, Veeger NJGM, Hamulyak K, Prins MH, Buller HR, et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation. 2010;121:1706–12.CrossRefGoogle Scholar
  32. 32.
    Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293:2352–61.CrossRefGoogle Scholar
  33. 33.
    Ribeiro DD, Lijfering WM, Barreto SM, Lopes FD, Pires G de S, Rosendaal FR, et al. The influence of prothrombotic laboratory abnormalities on the risk of recurrent venous thrombosis. Thromb Res. 2012;130:974–6.CrossRefGoogle Scholar
  34. 34.
    Santamaria MG, Agnelli G, Taliani MR, Prandoni P, Moia M, Bazzan M, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res. 2005;116:301–6.CrossRefGoogle Scholar
  35. 35.
    Jacobsen AF, Sandset PM. Venous thromboembolism associated with pregnancy and hormonal therapy. Best Pract Res Clin Haematol. 2012;25:319–32.CrossRefGoogle Scholar
  36. 36.
    Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol. 2012;32:563–8.CrossRefGoogle Scholar
  37. 37.
    Cushman M, Glynn RJ, Goldhaber SZ, Moll S, Bauer KA, Deitcher S, et al. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost. 2006;4:2199–203.CrossRefGoogle Scholar
  38. 38.
    Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJM. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6:632–7.CrossRefGoogle Scholar
  39. 39.
    Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697–706.CrossRefGoogle Scholar
  40. 40.
    Bates SM. Pregnancy-associated venous thromboembolism: prevention and treatment. Semin Hematol. 2011;48:271–84.CrossRefGoogle Scholar
  41. 41.
    White RH, Chan W-S, Zhou H, Ginsberg JS. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb Haemost. 2008;100:246–52.CrossRefGoogle Scholar
  42. 42.
    Galanaud J-P, Sevestre M-A, Genty C, Kahn SR, Pernod G, Rolland C, et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost. 2014;12:436–43.CrossRefGoogle Scholar
  43. 43.
    Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost. 2010;8:2436–42.CrossRefGoogle Scholar
  44. 44.
    Carrier M, Rodger MA, Wells PS, Righini M, Le Gal G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost. 2011;9:1119–25.CrossRefGoogle Scholar
  45. 45.
    Donadini MP, Ageno W, Antonucci E, et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis. Thromb Haemost. 2013;111:172–9.PubMedGoogle Scholar
  46. 46.
    Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–8.CrossRefGoogle Scholar
  47. 47.
    Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012;126:448–54.CrossRefGoogle Scholar
  48. 48.
    den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J Thromb Haemost. 2013;11:998–1000.CrossRefGoogle Scholar
  49. 49.
    • Chee CE, Ashrani AA, Marks RS, Petterson TM, Bailey KR, Melton LJ, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123:3972–8 A detailed population-based cohort study looking at trends of venous thromboembolism recurrence by cancer type.CrossRefGoogle Scholar
  50. 50.
    Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149:323–33.CrossRefGoogle Scholar
  51. 51.
    Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, et al. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med. 2015;373:697–704.CrossRefGoogle Scholar
  52. 52.
    Robin P, Le Roux P-Y, Le Moigne E, et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thromb Res. 2017;155:6–9.CrossRefGoogle Scholar
  53. 53.
    Coyle K, Carrier M, Lazo-Langner A, Shivakumar S, Zarychanski R, Tagalakis V, et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thromb Res. 2017;151:67–71.CrossRefGoogle Scholar
  54. 54.
    •• Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2017;15:2076–9 Recent guideline statement from the ISTH with specific recommendations on screening for occult malignancy in patients with venous thromboembolism.CrossRefGoogle Scholar
  55. 55.
    Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780–9.CrossRefGoogle Scholar
  56. 56.
    Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149(481–90):W94.Google Scholar
  57. 57.
    Bruinstroop E, Klok FA, Van De Ree MA, Oosterwijk FL, Huisman MV. Elevated d-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost. 2009;7:611–8.CrossRefGoogle Scholar
  58. 58.
    Kearon C, Spencer FA, O’Keeffe D, et al. d-Dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy. Ann Intern Med. 2015;162:27.CrossRefGoogle Scholar
  59. 59.
    Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. Can Med Assoc J. 2008;179:417–26.CrossRefGoogle Scholar
  60. 60.
    Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630–6.CrossRefGoogle Scholar
  61. 61.
    Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10:1019–25.CrossRefGoogle Scholar
  62. 62.
    Ensor J, Riley RD, Moore D, Snell KIE, Bayliss S, Fitzmaurice D. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open. 2016;6:e011190.CrossRefGoogle Scholar
  63. 63.
    Marcucci M, Iorio A, Douketis JD, Eichinger S, Tosetto A, Baglin T, et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna prediction model with pooled individual patient data. J Thromb Haemost. 2015;13:775–81.CrossRefGoogle Scholar
  64. 64.
    Tritschler T, Méan M, Limacher A, Rodondi N, Aujesky D. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna prediction model. Blood. 2015;126:1949–51.CrossRefGoogle Scholar
  65. 65.
    Rodger MA, Le Gal G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:j1065.CrossRefGoogle Scholar
  66. 66.
    Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–7.CrossRefGoogle Scholar
  67. 67.
    Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med. 2001;345:165–9.CrossRefGoogle Scholar
  68. 68.
    Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism. JAMA. 2015;314:31–40.CrossRefGoogle Scholar
  69. 69.
    Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425–34.CrossRefGoogle Scholar
  70. 70.
    Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–9.CrossRefGoogle Scholar
  71. 71.
    Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959–67.CrossRefGoogle Scholar
  72. 72.
    • Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211–22 Important reference that demonstrated the efficacy of a direct oral anticoagulant, rivaroxaban, in the extended treatment of venous thromboembolism.CrossRefGoogle Scholar
  73. 73.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefGoogle Scholar
  74. 74.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefGoogle Scholar
  75. 75.
    Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefGoogle Scholar
  76. 76.
    • EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510 Important reference that demonstrated the efficacy of a direct oral anticoagulant, rivaroxaban, in treatment of venous thromboembolism.CrossRefGoogle Scholar
  77. 77.
    • Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52 Important reference that demonstrated the efficacy of a direct oral anticoagulant, dabigatran, in treatment of venous thromboembolism.CrossRefGoogle Scholar
  78. 78.
    • Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708 Important reference that demonstrated the efficacy of a direct oral anticoagulant, apixiban, in extended treatment of venous thromboembolism. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Cardiology, Department of Medicine, Heart and Vascular InstituteVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations